News
BioMarin is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) drug once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback